Last reviewed · How we verify
Higher dose marketed paracetamol — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Higher dose marketed paracetamol (Higher dose marketed paracetamol) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Higher dose marketed paracetamol TARGET | Higher dose marketed paracetamol | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Higher dose marketed paracetamol CI watch — RSS
- Higher dose marketed paracetamol CI watch — Atom
- Higher dose marketed paracetamol CI watch — JSON
- Higher dose marketed paracetamol alone — RSS
Cite this brief
Drug Landscape (2026). Higher dose marketed paracetamol — Competitive Intelligence Brief. https://druglandscape.com/ci/higher-dose-marketed-paracetamol. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab